001     168332
005     20240229133604.0
024 7 _ |a 10.1016/j.radonc.2021.03.024
|2 doi
024 7 _ |a pmid:33838170
|2 pmid
024 7 _ |a 0167-8140
|2 ISSN
024 7 _ |a 1879-0887
|2 ISSN
024 7 _ |a altmetric:103678980
|2 altmetric
037 _ _ |a DKFZ-2021-00835
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rares Franco, Nicola
|b 0
245 _ _ |a Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity.
260 _ _ |a Amsterdam [u.a.]
|c 2021
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1619619875_10045
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Apr 8;159:241-248
520 _ _ |a To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi).Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream. Among 43 literature-identified SNPs, the 30% most strongly associated with each toxicity were tested. SNP-SNP combinations (named SNP-allele sets) seen in ≥10% of the cohort were condensed into risk (RS) and protection (PS) scores, respectively indicating increased or decreased toxicity risk. Performance of RS and PS was evaluated by logistic regression. RS and PS were then combined into a single PRSi evaluated by area under the receiver operating characteristic curve (AUC).Among 1,387 analysed patients, toxicity rates were 11.7% (rectal bleeding), 4.0% (urinary frequency), 5.5% (haematuria), 7.8% (nocturia) and 17.1% (decreased urinary stream). RS and PS combined 8 to 15 different SNP-allele sets, depending on the toxicity endpoint. Distributions of PRSi differed significantly in patients with/without toxicity with AUCs ranging from 0.61 to 0.78. PRSi was better than the classical summed PRS, particularly for the urinary frequency, haematuria and decreased urinary stream endpoints.Our method incorporates SNP-SNP interactions when calculating PRS for radiotherapy toxicity. Our approach is better than classical summation in discriminating patients with toxicity and should enable incorporating genetic information to improve normal tissue complication probability models.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|x 0
|f POF IV
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a SNPs
|2 Other
650 _ 7 |a epistasis
|2 Other
650 _ 7 |a genetic risk factors
|2 Other
650 _ 7 |a late toxicity
|2 Other
650 _ 7 |a prostate cancer
|2 Other
650 _ 7 |a radiotherapy
|2 Other
700 1 _ |a Carlotta Massi, Michela
|b 1
700 1 _ |a Ieva, Francesca
|b 2
700 1 _ |a Manzoni, Andrea
|b 3
700 1 _ |a Maria Paganoni, Anna
|b 4
700 1 _ |a Zunino, Paolo
|b 5
700 1 _ |a Veldeman, Liv
|b 6
700 1 _ |a Ost, Piet
|b 7
700 1 _ |a Fonteyne, Valérie
|b 8
700 1 _ |a Talbot, Christopher J
|b 9
700 1 _ |a Rattay, Tim
|b 10
700 1 _ |a Webb, Adam
|b 11
700 1 _ |a Johnson, Kerstie
|b 12
700 1 _ |a Lambrecht, Maarten
|b 13
700 1 _ |a Haustermans, Karin
|b 14
700 1 _ |a De Meerleer, Gert
|b 15
700 1 _ |a de Ruysscher, Dirk
|b 16
700 1 _ |a Vanneste, Ben
|b 17
700 1 _ |a Van Limbergen, Evert
|b 18
700 1 _ |a Choudhury, Ananya
|b 19
700 1 _ |a Elliott, Rebecca M
|b 20
700 1 _ |a Sperk, Elena
|b 21
700 1 _ |a Veldwijk, Marlon
|b 22
700 1 _ |a Herskind, Carsten
|b 23
700 1 _ |a Avuzzi, Barbara
|b 24
700 1 _ |a Noris Chiorda, Barbara
|b 25
700 1 _ |a Valdagni, Riccardo
|b 26
700 1 _ |a Azria, David
|b 27
700 1 _ |a Farcy-Jacquet, Marie-Pierre
|b 28
700 1 _ |a Brengues, Muriel
|b 29
700 1 _ |a Rosenstein, Barry S
|b 30
700 1 _ |a Stock, Richard G
|b 31
700 1 _ |a Vega, Ana
|b 32
700 1 _ |a Elías Aguado-Barrera, Miguel
|b 33
700 1 _ |a Sosa-Fajardo, Paloma
|b 34
700 1 _ |a Dunning, Alison M
|b 35
700 1 _ |a Fachal, Laura
|b 36
700 1 _ |a Kerns, Sarah L
|b 37
700 1 _ |a Payne, Debbie
|b 38
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 39
|u dkfz
700 1 _ |a Seibold, Petra
|0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
|b 40
|u dkfz
700 1 _ |a Ml West, Catharine
|b 41
700 1 _ |a Rancati, Tiziana
|b 42
700 1 _ |a Consortium, REQUITE
|b 43
|e Collaboration Author
700 1 _ |a Lievens, Yolande
|b 44
700 1 _ |a van Eijkeren, Marc
|b 45
700 1 _ |a Monten, Christel
|b 46
700 1 _ |a De Neve, Wilfried
|b 47
700 1 _ |a Peeters, Stephanie
|b 48
700 1 _ |a Weltens, Caroline
|b 49
700 1 _ |a Defraene, Gilles
|b 50
700 1 _ |a van Limberghen, Erik
|b 51
700 1 _ |a Briers, Erik
|b 52
700 1 _ |a Bourgier, Celine
|b 53
700 1 _ |a Draghici, Roxana
|b 54
700 1 _ |a Bons, Francoise
|b 55
700 1 _ |a Blaschke, Thomas
|b 56
700 1 _ |a Weiß, Christian
|b 57
700 1 _ |a Helmbold, Irmgard
|b 58
700 1 _ |a Weißenberger, Christian
|b 59
700 1 _ |a Stegmaier, Petra
|b 60
700 1 _ |a Claßen, Johannes
|b 61
700 1 _ |a Giesche, Ulrich
|b 62
700 1 _ |a Sautter-Bihl, Marie-Luise
|b 63
700 1 _ |a Neu, Burkhard
|b 64
700 1 _ |a Schnabel, Thomas
|b 65
700 1 _ |a Ehmann, Michael
|b 66
700 1 _ |a Gauter-Fleckenstein, Benjamin
|b 67
700 1 _ |a Schäfer, Jörg
|b 68
700 1 _ |a Giandini, Tommaso
|b 69
700 1 _ |a Franceschini, Marzia
|b 70
700 1 _ |a Sangalli, Claudia
|b 71
700 1 _ |a Morlino, Sara
|b 72
700 1 _ |a Lozza, Laura
|b 73
700 1 _ |a De Santis, Maria C
|b 74
700 1 _ |a Pietro, Gabriele
|b 75
700 1 _ |a Delmastro, Elena
|b 76
700 1 _ |a Garibaldi, Elisabetta
|b 77
700 1 _ |a Cicchetti, Alessandro
|b 78
700 1 _ |a Piqué-Leiva, Bibiana
|b 79
700 1 _ |a Molla, Meritxel
|b 80
700 1 _ |a Giraldo, Alexandra
|b 81
700 1 _ |a Ramos, Monica
|b 82
700 1 _ |a Lobato-Busto, Ramon
|b 83
700 1 _ |a Torrado Moya, Laura
|b 84
700 1 _ |a Dominguez-Rios, Isabel
|b 85
700 1 _ |a Fajardo-Paneque, Irene
|b 86
700 1 _ |a Calvo-Crespo, Patricia
|b 87
700 1 _ |a Carballo, Ana
|b 88
700 1 _ |a Peleteiro, Paula
|b 89
700 1 _ |a Olivia-Fuentes-Rios
|b 90
700 1 _ |a Gomez-Caamano, Antonio
|b 91
700 1 _ |a Harrop, Victoria
|b 92
700 1 _ |a Payne, Debbie
|b 93
700 1 _ |a Keni, Manjusha
|b 94
700 1 _ |a Symonds, Paul R
|b 95
700 1 _ |a Lavers, Samuel
|b 96
700 1 _ |a Wright, Simon
|b 97
700 1 _ |a Thiagarajan, Sridhar
|b 98
700 1 _ |a Aznar-Garcia, Luis
|b 99
700 1 _ |a Kancherla, Kiran
|b 100
700 1 _ |a Kent, Christopher
|b 101
700 1 _ |a Vasanthan, Subramaniam
|b 102
700 1 _ |a Appleton, Donna
|b 103
700 1 _ |a Kaushik, Monika
|b 104
700 1 _ |a Kenny, Frances
|b 105
700 1 _ |a Khout, Hazem
|b 106
700 1 _ |a Krupa, Jaroslaw
|b 107
700 1 _ |a Lambert, Kelly V
|b 108
700 1 _ |a Pilgrim, Simon
|b 109
700 1 _ |a Shokuhi, Sheila
|b 110
700 1 _ |a Valassiadou, Kalliope
|b 111
700 1 _ |a Bioangiu, Ion
|b 112
700 1 _ |a Sampson, Kufre
|b 113
700 1 _ |a Osman, Ahmed
|b 114
700 1 _ |a Faivre-Finn, Corinne
|b 115
700 1 _ |a Foweraker, Karen
|b 116
700 1 _ |a Pascoe, Abigail
|b 117
700 1 _ |a Esler, Claire P
|b 118
700 1 _ |a Ward, Tim
|b 119
700 1 _ |a Higginson, Daniel S
|b 120
700 1 _ |a Green, Sheryl
|b 121
773 _ _ |a 10.1016/j.radonc.2021.03.024
|g p. S0167814021061612
|0 PERI:(DE-600)1500707-8
|p 241-248
|t Radiotherapy and oncology
|v 159
|y 2021
|x 0167-8140
909 C O |o oai:inrepo02.dkfz.de:168332
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 39
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 40
|6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-31
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-31
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-31
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b RADIOTHER ONCOL : 2019
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-31
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-31
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-01-31
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21